Navigation Links
American Oriental Bioengineering Appoints Anindya Chatterjee to Chief Strategy Officer
Date:6/9/2008

- Anindya Chatterjee Brings Over Thirteen Years of Capital Markets

Experience to AOBO - - New Role Emphasizes Strategic Growth Plan and Capital Markets Interaction

-

NEW YORK, June 9 /PRNewswire-FirstCall/ -- American Oriental Bioengineering, Inc. (NYSE: AOB) ("AOB" or "the Company"), a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter ("OTC") products in China, today announced the appointment of Anindya Chatterjee to Chief Strategy Officer, effective May 23, 2008. Based in New York, Anindya Chatterjee will report to Lily Li, Chief Financial Officer, Chief Operating Officer and co-founder of the Company.

Anindya Chatterjee will work closely with AOBO's management team to shape and execute the Company's core growth initiatives, including acquisition-led expansion and capital markets strategy. Further, he will also serve as the Company's interface with the investment community, playing a crucial role in enhancing investor communications and transparency.

Anindya Chatterjee brings more than thirteen years of capital markets experience to AOBO. He was previously a Managing Director in equity research at Jefferies & Co, where he headed Emerging Asian (China & India) equity research. He was also a Strategist and Economist focused on Non-Japan Asia for Bear Stearns & Company in Hong Kong. He held similar positions at IDEA INC. in New York, and NatWest Markets in Singapore, where he was the Emerging Markets Strategist and Regional Economist and Equity Strategist, respectively. He also was the Head of Research at ANZ Investment Bank in India, and held research positions at HSBC Securities and Smith New Court Securities.

Tony Liu, AOBO's Chief Executive Officer and Chairman stated, "We are excited to add Anindya to our core management team at this crucial time of rapid business expansion. Anindya brings a deep understanding our Company, our sector and our corporate culture in addition to his invaluable capital markets experience, and long-standing credibility among global institutional investors."

Anindya Chatterjee stated, "As an equity analyst, I have interacted regularly with AOBO's investors and management team, and I am very pleased to accept this strategic role at a Company with such strong fundamental performance, exciting growth prospects, and cohesive team. With my investment research experience and knowledge of the capital markets, I look forward to enhancing and executing AOBO's key growth initiatives, including the acquisition strategy and navigating the U.S. capital markets."

About American Oriental Bioengineering Inc.

American Oriental Bioengineering Inc. is a pharmaceutical company dedicated to improving health through the development, manufacture and commercialization of a broad range of prescription and over the counter products in China. For more information, visit http://www.bioaobo.com.

Statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. The economic, competitive, governmental, technological and other factors identified in the Company's filings with the Securities and Exchange Commission, including the Form 10-K for the year ended December 31, 2007, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.


'/>"/>
SOURCE American Oriental Bioengineering, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
3. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
4. American Oriental Bioengineering Announces Participation in September Investor Conferences
5. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
6. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
7. Tips from the Journals of the American Society for Microbiology
8. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
9. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
10. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
11. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
(Date:6/23/2016)... FRANCISCO , June 23, 2016   EpiBiome ... has secured $1 million in debt financing from Silicon ... ramp up automation and to advance its drug development ... its new facility. "SVB has been an ... beyond the services a traditional bank would provide," said ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... exhibiting at the Pennsylvania Convention Center and will showcase its product’s latest features ... will also be presenting a scientific poster on Disrupting Clinical Trials in The ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... 31, 2016   ... the "Company") LegacyXChange is excited to release ... soon to be launched online site for trading 100% ... ) will also provide potential shareholders a sense of ... to an industry that is notorious for fraud. The ...
Breaking Biology News(10 mins):